Intrathecal administration

Therapeutic Vaccines Market Size and Share to Surpass USD 87 Billion by 2035 - Exclusive Report by Roots Analysis

Retrieved on: 
Tuesday, January 9, 2024

LONDON, Jan. 9, 2024 /PRNewswire/ -- The global therapeutic vaccines market is estimated to be worth USD 2 billion in 2023 and is anticipated to reach USD 87 billion by 2035. It is expected to grow at a compounded annual growth rate (CAGR) of 35% during the forecast period from 2023 to 2035.

Key Points: 
  • The therapeutic vaccines market is also driven by the expanding pipeline of therapeutic vaccine candidates in the clinical development stages.
  • Based on the type of vaccine, the therapeutic vaccines market is segmented into antigen vaccines, dendritic vaccines, DNA vaccines, and peptide vaccines.
  • Based on the type of method of vaccine composition, the therapeutic vaccines market is segmented into autologous vaccines, allogeneic vaccines and other methods.
  • Europe will dominate the therapeutic vaccines market and is anticipated to capture 59% of the overall revenue share in 2023.

Therapeutic Vaccines Market Size and Share to Surpass USD 87 Billion by 2035 - Exclusive Report by Roots Analysis

Retrieved on: 
Tuesday, January 9, 2024

LONDON, Jan. 9, 2024 /PRNewswire/ -- The global therapeutic vaccines market is estimated to be worth USD 2 billion in 2023 and is anticipated to reach USD 87 billion by 2035. It is expected to grow at a compounded annual growth rate (CAGR) of 35% during the forecast period from 2023 to 2035.

Key Points: 
  • The therapeutic vaccines market is also driven by the expanding pipeline of therapeutic vaccine candidates in the clinical development stages.
  • Based on the type of vaccine, the therapeutic vaccines market is segmented into antigen vaccines, dendritic vaccines, DNA vaccines, and peptide vaccines.
  • Based on the type of method of vaccine composition, the therapeutic vaccines market is segmented into autologous vaccines, allogeneic vaccines and other methods.
  • Europe will dominate the therapeutic vaccines market and is anticipated to capture 59% of the overall revenue share in 2023.

SciSparc Granted Patent from the Australian Patent Office for its Reduction of Opioids Use in Pain Management Technology

Retrieved on: 
Tuesday, October 31, 2023

The Patent has been granted by IP Australia, the government agency in Australia that administers intellectual property rights and legislation for patents.

Key Points: 
  • The Patent has been granted by IP Australia, the government agency in Australia that administers intellectual property rights and legislation for patents.
  • The increasing rate of regulatory approvals and the launch of new opioid medicines to treat patients with chronic pain are the factors expected to drive market growth.
  • At the same time, opioid abuse and addiction has been a global growing epidemic for more than a decade.
  • "The fact that SciSparc's number of granted patents continues to grow is proof recognizing the innovation that characterizes the technologies in the Company's pipeline.

World Alzheimer's Disease Therapeutics Analysis Report 2022: 101 Active Drugs - Market Insight, Epidemiology and Pipeline Assessment by Molecule Type, Route of Administration, Pipeline Phase - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 20, 2022

The "Alzheimer's Disease Therapeutics (2022 Edition) - Market Insight, Epidemiology and Pipeline Assessment (By Molecule Type, By Route of Administration, By Pipeline Phase)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Alzheimer's Disease Therapeutics (2022 Edition) - Market Insight, Epidemiology and Pipeline Assessment (By Molecule Type, By Route of Administration, By Pipeline Phase)" report has been added to ResearchAndMarkets.com's offering.
  • Alzheimer's disease Therapeutics Pipeline Analysis has 101 active drugs undergoing several stages of clinical trials.
  • The Alzheimer's disease Therapeutics Pipeline is driven by an increasing gap of unmet need of effective therapeutics that can cure Alzheimer's disease.
  • The report analyses the Alzheimer's disease Therapeutics by Pipeline Phase (Phase I, Phase I/II, Phase II, Phase II/III, Phase III, Phase IV, Preclinical).

Global Opioids Market Report 2022: Featuring Purdue, Johnson & Johnson, Hikma Pharmaceuticals, Pfizer, Abbvie, Sanofi, Sun Pharmaceutical, Grunenthal & Merck - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 16, 2022

Emergence of non-addictive alternative products to opioids for pain-management leads to decline in the growth of opioid market. According to American Society of Anesthesiologists, there are several non-opioid medicines that are available over the counter--steroids and NSAIDs such as aspirin, ibuprofen, and acetaminophen among others. Furthermore, wide availability and low cost associated with these drugs contribute to increase in demand for such products during the forecast period. For instance, aspirin cost USD 10 for a pack of 30 tablets.

Key Points: 
  • The global opioids market size is expected to reach USD 25.33 billion by 2030, registering CAGR of 1.2% during the forecast period.
  • Growing use of opioids for the management of post-operative pain, caused due to surgeries, is expected to drive the market growth.
  • Emergence of non-addictive alternative products to opioids for pain-management leads to decline in the growth of opioid market.
  • The growth of the region can be attributed to increasing geriatric population which are susceptible to the chronic pain
    Chapter 4 Global Opioids Market - Segment Analysis, By Product, 2018 - 2030 (USD Million)
    Chapter 5 Global Opioids Market - Segment Analysis, by Application, 2018 - 2030 (USD Million)
    Chapter 6 Global Opioids Market - Segment Analysis, by Route of Administration, 2018 - 2030 (USD Million)
    Chapter 7 Global Opioids Market - Segment Analysis, by Distribution Channel, 2018 - 2030 (USD Million)
    Chapter 9 Global Opioids Market: Competitive Analysis

Additional Preclinical Data Supports Clinical Advancement of First AAV-Based Gene Therapy for Adrenomyeloneuropathy

Retrieved on: 
Tuesday, May 17, 2022

These data support the ongoing clinical advancement of SBT101 as a potential treatment for adrenomyeloneuropathy (AMN), a progressive, inherited, and debilitating neurodegenerative disease.

Key Points: 
  • These data support the ongoing clinical advancement of SBT101 as a potential treatment for adrenomyeloneuropathy (AMN), a progressive, inherited, and debilitating neurodegenerative disease.
  • The SBT101 preclinical data, presented at the American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting in Washington, DC, demonstrate dose-dependent functional improvement as measured by grip strength in a mouse model of AMN.
  • SwanBio Therapeutics is a gene therapy company that aims to bring life-changing treatments to people with devastating, inherited neurological conditions.
  • SwanBios lead program is being advanced toward clinical development for the treatment of adrenomyeloneuropathy (AMN).

SwanBio Therapeutics to Present Preclinical Data on Lead Candidate at American Society of Gene & Cell Therapy

Retrieved on: 
Tuesday, April 19, 2022

SwanBio Therapeutics, a gene therapy company advancing AAV-based therapies for the treatment of devastating, inherited neurological conditions, will present safety, efficacy, and biodistribution data from preclinical studies of its lead candidate, SBT101, for the treatment of adrenomyeloneuropathy (AMN) at the American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting in Washington, DC May 16-19.

Key Points: 
  • SwanBio Therapeutics, a gene therapy company advancing AAV-based therapies for the treatment of devastating, inherited neurological conditions, will present safety, efficacy, and biodistribution data from preclinical studies of its lead candidate, SBT101, for the treatment of adrenomyeloneuropathy (AMN) at the American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting in Washington, DC May 16-19.
  • These data have formed the basis of SwanBios progress to advance SBT101 into clinical trials.
  • SwanBio Therapeutics is a gene therapy company that aims to bring life-changing treatments to people with devastating, inherited neurological conditions.
  • SwanBio is supported by long-term, committed investment partners, including its primary investors Syncona, Ltd. (lead investor and majority shareholder) and Mass General Brigham Ventures.

Updated Preclinical Data Support Potential of First AAV-Based Gene Therapy as a Treatment for Adrenomyeloneuropathy

Retrieved on: 
Tuesday, April 5, 2022

These data support the potential of SBT101 as a treatment for adrenomyeloneuropathy (AMN), a progressive, inherited, and debilitating neurodegenerative disease caused by a deficiency in the ABCD1 gene which primarily affects the spinal cord.

Key Points: 
  • These data support the potential of SBT101 as a treatment for adrenomyeloneuropathy (AMN), a progressive, inherited, and debilitating neurodegenerative disease caused by a deficiency in the ABCD1 gene which primarily affects the spinal cord.
  • SwanBio will present additional data during the AAN virtual meeting April 24-26, 2022.
  • These data represent the tremendous progress weve made to date on our pipeline and scientific platform.
  • SwanBio Therapeutics is a gene therapy company that aims to bring life-changing treatments to people with devastating, inherited neurological conditions.

SwanBio Therapeutics to Present New Preclinical Data Showcasing AAV-Based Gene Therapy Candidate for Adrenomyeloneuropathy at American Academy of Neurology Annual Meeting

Retrieved on: 
Friday, March 4, 2022

SwanBio Therapeutics, a gene therapy company advancing AAV-based therapies for the treatment of devastating, inherited neurological conditions, today announced that the company will present data supporting the clinical advancement of its lead candidate, SBT101, at the American Academy of Neurology (AAN) 2022 Annual Meeting.

Key Points: 
  • SwanBio Therapeutics, a gene therapy company advancing AAV-based therapies for the treatment of devastating, inherited neurological conditions, today announced that the company will present data supporting the clinical advancement of its lead candidate, SBT101, at the American Academy of Neurology (AAN) 2022 Annual Meeting.
  • The meeting is being held in Seattle April 2-7, 2022, and virtually April 24-26, 2022.
  • In preclinical non-human primate models, weve observed good tolerability and dose-dependent biodistribution in the CNS with SBT101, which we believe will translate into patients in the clinic.
  • SwanBio Therapeutics is a gene therapy company that aims to bring life-changing treatments to people with devastating, inherited neurological conditions.

Global Spinal Muscular Atrophy Treatment Market Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 21, 2021

The "Global Spinal Muscular Atrophy Treatment Market (2021-2026) by Disease Type, Treatment, Route of Administration, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Spinal Muscular Atrophy Treatment Market (2021-2026) by Disease Type, Treatment, Route of Administration, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The Global Spinal Muscular Atrophy Treatment Market is estimated to be USD 1.1 Bn in 2021 and is expected to reach USD 1.98 Bn by 2026, growing at a CAGR of 12.
  • The SMA treatment market is growing at a significant rate due to the increasing prevalence of spinal muscular atrophy and rising awareness about diagnostics and treatment of SMA.
  • Factors such as the rising importance of rare diseases, increasing initiatives for creating awareness of SMA and growing research initiatives by market players for developing a treatment for SMA are drivers for the market.